Low levels of high-density lipoprotein cholesterol and increased risk of cardiovascular events in stable ischemic heart disease patients: A post-hoc analysis from the COURAGE trial (clinical outcomes utilizing revascularization and aggressive drug evaluation)

Journal of the American College of Cardiology

Volumn 62, Issue 20, 2013, Pages 1826-1833

  Acharjee, Subroto ^a   Boden, William E ^b   Hartigan, Pamela M ^c   Teo, Koon K ^d   Maron, David J ^e   Sedlis, Steven P ^f   Kostuk, William ^g   Spertus, John A ^h   Dada, Marcin ⁱ   Chaitman, Bernard R ^j   Mancini, G B John ^k   Weintraub, William S ^l  

^a EINSTEIN MEDICAL CENTER   (United States)

^b ALBANY MEDICAL COLLEGE   (United States)

^c VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^d MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

^e VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^f DEPARTMENT OF VETERANS AFFAIRS   (United States)

^g LONDON HEALTH SCIENCES CENTRE   (Canada)

^h UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

ⁱ HARTFORD HOSPITAL   (United States)

^j SAINT LOUIS UNIVERSITY   (United States)

^k UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^l CHRISTIANA CARE HEALTH SYSTEM   (United States)

more..

Author keywords

HDL cholesterol; residual risk; stable ischemic heart disease

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DEATH; FEMALE; FOLLOW UP; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; POST HOC ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION;

ACS; ACUTE CORONARY SYNDROME(S); ADULT TREATMENT PANEL; ATP; BMI; BODY MASS INDEX; CETP; CHOLESTERYL ESTER TRANSFER PROTEIN; HDL CHOLESTEROL; HDL-C; HIGH-DENSITY LIPOPROTEIN CHOLESTEROL; LDL-C; LOW-DENSITY LIPOPROTEIN CHOLESTEROL; MI; MYOCARDIAL INFARCTION; OMT; OPTIMAL MEDICAL THERAPY; PCI; PERCUTANEOUS CORONARY INTERVENTION; RESIDUAL RISK; SIHD; STABLE ISCHEMIC HEART DISEASE;

AGED; ANTICHOLESTEREMIC AGENTS; AZETIDINES; CHOLESTEROL, HDL; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KAPLAN-MEIER ESTIMATE; LIFE STYLE; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; NORTH AMERICA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SECONDARY PREVENTION;

EID: 84887150818     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2013.07.051     Document Type: Article

References (36)

1. T. Gordon, W.P. Castelli, M.C. Hjortland, W.B. Kannel, and T.R. Dawber High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study Am J Med 62 1977 707 714
2. P.W. Wilson, R.J. Garrison, W.P. Castelli, M. Feinleib, P.M. McNamara, and W.B. Kannel Prevalence of coronary heart disease in the Framingham Offspring Study: role of lipoprotein cholesterols Am J Cardiol 46 1980 649 654
3. W.P. Castelli, R.J. Garrison, P.W. Wilson, R.D. Abbott, S. Kalousdian, and W.B. Kannel Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study JAMA 256 1986 2835 2838
4. D.J. Gordon, J.L. Probstfield, and R.J. Garrison High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies Circulation 79 1989 8 15
5. G. Assmann, H. Schulte, A. von Eckardstein, and Y. Huang High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport Atherosclerosis 124 Suppl 1996 S11 S20
6. P.M. Ridker, J. Genest, S.M. Boekholdt for the JUPITER Trial Study Group HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial Lancet 376 2010 333 339
7. K.K. Ray, C.P. Cannon, R. Cairns, D.A. Morrow, P.M. Ridker, E. Braunwald for the TIMI Study Group Prognostic utility of apoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22 Arterioscler Thromb Vasc Biol 29 2009 424 430
8. P. Barter, A.M. Gotto, and J.C. LaRosa HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events N Engl J Med 357 2007 1301 1310
9. E.M. deGoma, N.J. Leeper, and P.A. Heidenreich Clinical significance of high-density lipoprotein cholesterol in patients with low low-density lipoprotein cholesterol J Am Coll Cardiol 51 2008 49 55
10. H. Jafri, A.A. Alsheikh-Ali, and R.H. Karas Meta-analysis: statin therapy does not alter the association between low levels of high-density lipoprotein cholesterol and increased cardiovascular risk Ann Intern Med 153 2010 800 808
11. W.E. Boden, R.A. O'Rourke, K.K. Teo for the COURAGE Trial Research Group Optimal Medical Therapy with or without PCI for stable coronary disease N Engl J Med 356 2007 1503 1516
12. D.J. Maron, W.E. Boden, R.A. O'Rourke for the COURAGE Trial Research Group Intensive multifactorial intervention for stable coronary artery disease: optimal medical therapy in the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) trial J Am Coll Cardiol 55 2010 1348 1358
13. S.M. Grundy, J.I. Cleeman, C.N. Merz for the Coordinating Committee of the National Cholesterol Education Program Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines J Am Coll Cardiol 44 2004 720 732
14. W.E. Boden, R.A. O'Rourke, and K.K. Teo Design and rationale of the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation (COURAGE) trial Veterans Affairs Cooperative Studies Program no. 424 Am Heart J 151 2006 1173 1179
15. National Cholesterol Education Program Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II) Circulation 89 1994 1333 1445
16. P.S. Sever, B. Dahlof, and N.R. Poulter Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial Lancet 361 2003 1149 1158
17. F.M. Sacks, M.A. Pfeffer, and L.A. Moye The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels N Engl J Med 335 1996 1001 1009
18. J. Shepherd, S.M. Cobbe, and I. Ford Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia N Engl J Med 333 1995 1301 1307
19. J.R. Downs, M. Clearfield, and S. Weis Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS JAMA 279 1998 1615 1622
20. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet 344 1994 1383 1389
21. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease JAMA 251 1984 351 364
22. C. Baigent, A. Keech, and P.M. Kearney Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins Lancet 366 2005 1267 1278
23. C. Baigent, L. Blackwell, and J. Emberson Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials Lancet 376 2010 1670 1681
24. P.J. Libby The forgotten majority: unfinished business in cardiovascular risk reduction J Am Coll Cardiol 46 2005 1225 1228
25. J.C. LaRosa, S.M. Grundy, and D.D. Waters Intensive lipid lowering with atorvastatin in patients with stable coronary disease N Engl J Med 352 2005 1425 1435
26. C.P. Cannon, E. Braunwald, C.H. McCabe for the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators Intensive versus moderate lipid lowering with statins after acute coronary syndromes N Engl J Med 350 2004 1495 1504
27. P. Deedwania, P. Barter, R. Carmena for the Treating to New Targets Investigators Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study Lancet 368 2006 919 928
28. A.G. Olsson, G.G. Schwartz, and M. Szarek High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL Trial Eur Heart J 26 2005 890 896
29. S.J. Robins, D. Collins, J.T. Wittes, V. Papademetriou, P.C. Deedwania, E.J. Schaefer VA-HIT Study Group. Veterans Affairs High-Density Lipoprotein Intervention Trial Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial JAMA 285 2001 1585 1591
30. AIM-HIGH Investigators W.E. Boden, and J.L. Probstfield Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy N Engl J Med 365 2011 2255 2267
31. Armitage J, for the HPS2-THRIVE Collaborative Group. HPS2-THRIVE: Randomized placebo-controlled trial of ER Niacin and laropriprant in 25,673 patients with pre-existing cardiovascular disease. Abstract presented at: American College of Cardiology Scientific Session 2013; March 9, 2013; San Francisco, CA.
32. C.P. Cannon, H.M. Dansky, M. Davidson for the DEFINE Investigators Design of the DEFINE trial: determining the EFficacy and tolerability of CETP INhibition with AnacEtrapib Am Heart J 158 2009 513 519
33. Eli Lilly and Company. A Study of Evacetrapib in High-Risk Vascular Disease (ACCELERATE). Available at: http://clinicaltrials.gov/show/NCT01687998. Accessed March 24, 2013.
34. P.J. Barter, M. Caulfield, M. Eriksson for the ILLUMINATE Investigators Effects of torcetrapib in patients at high risk for coronary events N Engl J Med 357 2007 2109 2122
35. G.G. Schwartz, A.G. Olsson, M. Abt for the dal-OUTCOMES Investigators Effects of dalcetrapib in patients with a recent acute coronary syndrome N Engl J Med 367 2012 2089 2099
36. E.M. deGoma, and D.J. Rader High-density lipoprotein particle number: a better measure to quantify high-density lipoprotein? J Am Coll Cardiol 60 2012 517 520